Gene Therapy for Neurodegenerative Diseases
For decades, neurodegenerative diseases were considered untreatable at their root cause. Gene therapy is changing that — by targeting the specific genetic and molecular drivers of Huntington's, ALS, Parkinson's, and Alzheimer's disease. Many approaches remain investigational, but trials are open today.
What gene therapy actually means in this context
"Gene therapy" is an umbrella term covering several distinct approaches. For neurodegenerative diseases, three families of approaches are being studied in current clinical trials:
1. Antisense Oligonucleotides (ASOs)
Short synthetic strands of DNA or RNA that bind to a disease-causing messenger RNA and tell the cell to destroy it — effectively turning down a faulty gene. ASOs are typically delivered via spinal injection so they can reach the brain and spinal cord. Tofersen (for SOD1-ALS) is the first ASO approved by the FDA for a neurodegenerative disease; tominersen and other Huntington's ASOs are in active trials.
2. AAV Gene Replacement and Gene Augmentation
Adeno-associated viral vectors (AAVs) carry a working copy of a gene — or a gene that produces a protective protein — directly to brain cells. In Parkinson's research, AAV-based therapies have been studied for delivering enzymes that produce dopamine. In Alzheimer's, researchers are studying AAV delivery of nerve growth factor and APOE2 (the protective APOE variant) into specific brain regions.
3. Gene Editing (CRISPR and base editing)
CRISPR and related tools can permanently edit DNA at a specific location. For neurodegeneration, gene editing approaches remain mostly preclinical, but early trials are exploring CRISPR-based silencing of mutant huntingtin in Huntington's disease and editing of pathogenic variants in inherited ALS.
Where gene therapy stands by disease
Each neurodegenerative disease has a different genetic landscape. The therapeutic strategy — and how mature the science is — differs accordingly.
Huntington's Disease
Most genetically tractable — single dominant gene
HD is caused by a single dominant mutation in the huntingtin (HTT) gene. Because the genetic cause is well-defined, HD has been a leading testbed for ASO and gene-silencing approaches. Several ASO trials targeting mutant HTT are ongoing, with mixed early results that are reshaping how the field thinks about timing of intervention.
Learn about Huntington's disease →ALS (Amyotrophic Lateral Sclerosis)
First FDA-approved neurodegenerative gene therapy
Roughly 10% of ALS cases are inherited, with SOD1 and C9ORF72 as the most common genetic causes. Tofersen, an ASO targeting SOD1, became the first FDA-approved gene-targeted therapy for a neurodegenerative disease. C9ORF72-targeted ASOs and gene therapies for other ALS-causing genes are in active clinical development.
Learn about ALS →Parkinson's Disease
AAV delivery to specific brain circuits
Parkinson's gene therapy research has explored AAV delivery of enzymes that produce dopamine, growth factors that protect dopaminergic neurons, and approaches targeting the GBA and LRRK2 genes that contribute to genetic forms of PD. Several AAV-based programs are in mid-stage clinical trials.
Parkinson's gene therapy trials →Alzheimer's Disease
Earlier-stage research, multiple targets
Alzheimer's is genetically more complex than HD or familial ALS. Gene therapy research is exploring AAV-delivered APOE2 (the protective APOE variant), nerve growth factor delivery to the basal forebrain, and ASO approaches targeting tau. Most programs are in early-phase trials, but the science is moving quickly.
Alzheimer's clinical trials →What to know before considering a gene therapy trial
Genetic confirmation usually matters
Many gene-targeted trials require genetic confirmation of a specific mutation (for example, SOD1 in ALS or HTT CAG-repeat expansion in HD). Genetic testing is often a prerequisite for screening.
Disease stage affects eligibility
Many trials enroll only at specific disease stages — sometimes presymptomatic carriers, sometimes early symptomatic patients, sometimes a defined window after diagnosis. Stage-specific eligibility is a common reason people are excluded.
Delivery is often invasive
ASOs typically require lumbar puncture for spinal delivery. AAV gene therapies for the brain may require neurosurgical delivery directly into specific regions. These procedures carry their own risks separate from the therapy itself.
Long-term safety is still being learned
Some gene therapy approaches are designed to be one-time, durable interventions. That durability also means side effects, if they occur, may be long-lasting. Long-term follow-up is part of every trial protocol.
This page is educational, not medical advice. Whether a specific gene therapy trial is right for you depends on your specific diagnosis, genetic profile, disease stage, overall health, and personal goals. Always discuss trial options with your treating neurologist.
Looking for a gene therapy trial?
We help patients and caregivers find clinical trials matching their diagnosis, location, and stage — including gene therapy trials for neurodegenerative diseases.